Fanning, Gregory C.
Zoulim, Fabien http://orcid.org/0000-0002-2245-0083
Hou, Jinlin
Bertoletti, Antonio http://orcid.org/0000-0002-2942-0485
Article History
Accepted: 9 July 2019
First Online: 27 August 2019
Change Date: 8 January 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing interests
: G.C.F. is an employee of Janssen Pharmaceuticals. A.B. participates in advisory boards/consultancy on hepatitis B virus (HBV) immune therapy for Gilead, Janssen, Vir, Jiangsu Simcere Pharmaceutical and Humabs BioMed; is the scientific founder of Lion TCR Pte. Ltd.; is an advisor for Arbutus, Assembly, Gilead, Janssen, Myr Pharma, Roche, Transgene and Vir Biotech; and has received research grants from Evotec and Roche. F.Z. participates in advisory boards on HBV for AbbVie, Aligos, Gilead, Janssen, Myr Pharma, Spring Bank, Roche, Transgene and Vir Biotech; and has received research grants from Evotec and Roche. J.H. participates in advisory boards/consultancy for AbbVie, Arbutus, Bristol–Myers Squibb, Gilead Sciences, Johnson & Johnson and Roche, and has received grants from Bristol–Myers Squibb and Johnson & Johnson.